DE1231690B - Process for the preparation of N, N-dibenzyl sulfamides - Google Patents
Process for the preparation of N, N-dibenzyl sulfamidesInfo
- Publication number
- DE1231690B DE1231690B DES95069A DES0095069A DE1231690B DE 1231690 B DE1231690 B DE 1231690B DE S95069 A DES95069 A DE S95069A DE S0095069 A DES0095069 A DE S0095069A DE 1231690 B DE1231690 B DE 1231690B
- Authority
- DE
- Germany
- Prior art keywords
- sulfamide
- general formula
- mol
- benzyl
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
DEUTSCHESGERMAN
PATENTAMTPATENT OFFICE
AUSLEGESCHRIFTEDITORIAL
Int. Cl.:Int. Cl .:
Nummer:
Aktenzeichen:
Anmeldetag:
Auslegetag:Number:
File number:
Registration date:
Display day:
C07cC07c
Deutsche KL: 12 ο-23/03 German KL: 12 ο -23/03
1231 690
S95069IVb/12o
19. Januar 1965
5. Januar 19671231 690
S95069IVb / 12o
January 19, 1965
5th January 1967
Die Erfindung betrifft Verfahren zur Herstellung von Ν,Ν-Dibenzylsulfamiden der allgemeinen For-The invention relates to a process for the preparation of Ν, Ν-dibenzyl sulfamides of the general formula
mel1 R R mel1 RR
N-SO2-NH2 IN-SO 2 -NH 2 I.
IOIO
RHRH
worin der Rest wahlweise für Wasserstoff oder Chlor stehen kann, und ist dadurch gekennzeichnet, daß
man in an sich bekannter Weise
a) ein Ν,Ν-Dibenzylamin der allgemeinen Formelllwherein the remainder can optionally stand for hydrogen or chlorine, and is characterized in that one in a manner known per se
a) a Ν, Ν-dibenzylamine of the general formula
R RR R
2525th
NHNH
R HR H
mit Sulfamid umsetzt oderreacts with sulfamide or
b) ein Ν,Ν-Dibenzylamin der Formel II zuerst mit Sulfurylchlorid und die so erhaltene Verbindung der allgemeinen Formel IIIb) a Ν, Ν-dibenzylamine of the formula II first with sulfuryl chloride and the compound thus obtained of the general formula III
R RR R
Verfahren zur Herstellung von
Ν,Ν-DibenzylsulfamidenProcess for the production of
Ν, Ν-dibenzyl sulfamides
Anmelder:Applicant:
Sandoz A. G., Basel (Schweiz)Sandoz A. G., Basel (Switzerland)
Vertreter:Representative:
Dr. W. Schalk, Dipl.-Ing. P. Wirth,Dr. W. Schalk, Dipl.-Ing. P. Wirth,
Dipl.-Ing. G. E. M. DannenbergDipl.-Ing. G. E. M. Dannenberg
und Dr. V. Schmied-Kowarzik, Patentanwälte,and Dr. V. Schmied-Kowarzik, patent attorneys,
Frankfurt/M., Große Eschenheimer Str. 39Frankfurt / M., Große Eschenheimer Str. 39
Als Erfinder benannt:
Dr. William J. Houlihan,
Mountain Lakes, N. J. (V. St. A.)Named as inventor:
Dr. William J. Houlihan,
Mountain Lakes, NJ (V. St. A.)
Beanspruchte Priorität:Claimed priority:
V. St. v. Amerika vom 22. Januar 1964 (339 354),V. St. v. America January 22, 1964 (339 354),
vom 8. Dezember 1964dated December 8, 1964
(416 907)(416 907)
c) mindestens
Formel IVc) at least
Formula IV
Mol einerMole one
Verbindung derConnection of
R RR R
NH2 NH 2
N-SO2-Cl IIIN-SO 2 -Cl III
R RR R
R HR H
mit Ammoniak umsetzt, oderreacts with ammonia, or
als freie Base oder in Form eines Salzes mit 1 Mol Sulfamid in Gegenwart von Pyridin umsetzt. as a free base or in the form of a salt with 1 mol of sulfamide in the presence of pyridine.
Beim Verfahren gemäß Ausführungsform c) werden symmetrische Verbindungen erhalten, d. h. solche, in denen beide Benzylreste in einem Molekül gleich sind.In the method according to embodiment c) symmetrical connections are obtained, d. H. such, in which both benzyl radicals in one molecule are the same.
Eine Ausführungsform des erfindungsgemäßen Verfahrens besteht darin, daß man eine Verbindung der allgemeinen Formel II mit Sulfamid in Gegenwart eines tertiären Amins als Lösungsmittel auf Temperaturen zwischen 50 und 2500C, vorteilhafterweise zwischen 55 und 1250C, z. B. Rückflußtemperatur des Reaktionsgemisches,'erhitzt.One embodiment of the process according to the invention consists in that a compound of the general formula II with sulfamide in the presence of a tertiary amine as solvent is heated to temperatures between 50 and 250 ° C., advantageously between 55 and 125 ° C., e.g. B. reflux temperature of the reaction mixture 'heated.
Als tertiäre Amine können erfindungsgemäß beispielsweise Trialkylamine, Monoaryldialkylamine oderAccording to the invention, for example trialkylamines, monoaryldialkylamines or
609 750/430609 750/430
basische, stickstoffhaltige Heterocyclen, wie z. B. Pyridine, Chinoline und N-nied. Alkyl-pyrrole, verwendet werden.basic, nitrogen-containing heterocycles, such as. B. pyridines, quinolines and N-nied. Alkyl pyrroles are used will.
Die Ausgangsprodukte der allgemeinen Formel II sind entweder bekannt oder können so hergestellt werden, daß man Verbindungen der allgemeinen Formel IV (s. oben) mit Verbindungen der allgemeinen Formel VThe starting products of the general formula II are either known or can be prepared in this way be that one compounds of the general formula IV (see above) with compounds of the general Formula V
R RR R
J V J V
CH2 — ClCH 2 - Cl
R HR H
worin R die obige Bedeutung besitzt, in einem inerten organischen Lösungsmittel und in Gegenwart eines säurebindenden Agens umsetzt. Als säurebindendes Agens kann auch die Verbindung der allgemeinen Formel IV im Überschuß verwendet werden.wherein R has the above meaning, in an inert organic solvent and in the presence of one acid-binding agent converts. The compound of the general Formula IV can be used in excess.
Die erfindungsgemäß hergestellten Verbindungen der allgemeinen Formel I zeichnen sich durch einen primär stimulierenden Effekt auf das Zentralnervensystem aus, und zwar besonders das N,N-Dibenzylsulfamid. Diejenigen erfindungsgemäß hergestellten Verbindungen, deren Phenylreste durch mindestens 1 Chloratom substituiert sind, besitzen außerdem krampflösende und blutdrucksenkende Wirkung.The compounds of the general formula I prepared according to the invention are distinguished by a primary stimulating effect on the central nervous system, especially the N, N-dibenzylsulfamide. Those compounds prepared according to the invention whose phenyl radicals are at least 1 chlorine atom are substituted, also have antispasmodic and antihypertensive effects.
Die erfindungsgemäß hergestellten Verbindungen der allgemeinen Formel I, vor allem das N,N-Dibenzylsulfamid, sollen daher in der Therapie als Antidepressiva verwendet werden, die chlorsubstituierten Ν,Ν-Dibenzylsulfamide als Anticonvulsiva und das N-l^-Dichlorbenzyl-N-benzylsulfamid als blutdrucksenkendes Mittel. Die mittlere tägliche Dosis beträgt für das Ν,Ν-Dibenzylsulfamid zwischen 35 und 42 mg, für die anderen Verbindungen zwischen 200 und 350 mg.The compounds of general formula I prepared according to the invention, especially N, N-dibenzylsulfamide, should therefore be used in therapy as antidepressants that are chlorine-substituted Ν, Ν-dibenzylsulfamide as anticonvulsants and the N-l ^ -dichlorobenzyl-N-benzylsulfamide as antihypertensive agent. The mean daily dose for the Ν, Ν-dibenzylsulfamide is between 35 and 42 mg, for the other compounds between 200 and 350 mg.
In den nachfolgenden Beispielen, die die Ausführungen des Verfahrens erläutern, erfolgen alle Temperaturangaben in Celsiusgraden und sind unkorrigiert. In the following examples, which explain the implementation of the process, all are carried out Temperatures in degrees Celsius and are uncorrected.
Beispiel 1
Ν,Ν-Dibenzylsulfamidexample 1
Ν, Ν-dibenzylsulfamide
Eine Lösung von 21,7 g (0,11 Mol) Dibenzylamin und 9,6 g (0,1 Mol) Sulfamid in 40 ecm Pyridin wird unter Rühren am Rückfluß so lange erhitzt, bis keine Gasentwicklung mehr festzustellen ist. Das Lösungsmittel wird im Vakuum am Rotationsverdampfer entfernt und der viskose Rückstand aus Methanol— Wasser umkristallisiert. Das dabei erhaltene Ν,Ν-Dibenzylsulfamid hat einen Schmp. von 71,5 bis 74°.A solution of 21.7 g (0.11 mol) of dibenzylamine and 9.6 g (0.1 mol) of sulfamide in 40 ecm of pyridine becomes heated under reflux with stirring until no more gas evolution can be detected. The solvent is removed in vacuo on a rotary evaporator and the viscous residue from methanol- Recrystallized water. The Ν, Ν-dibenzylsulfamide obtained has a melting point of 71.5 to 74 °.
Beispiel 2
N-Benzyl-N-3,4-dichlorbenzylsulfamidExample 2
N-Benzyl-N-3,4-dichlorobenzylsulfamide
a) N-Benzyl-3,4-dichlorbenzylamina) N-Benzyl-3,4-dichlorobenzylamine
Eine Mischung, bestehend aus 107 g (1,0 Mol) Benzylamin, 78 g (0,4 Mol) <x,3,4-Trichlortoluol und 400 ecm absolutem Toluol, wird während 15 Stunden unter Rühren am Rückfluß erhitzt. Nach Abkühlung auf Raumtemperatur wird das ausgefallene Benzylamin-hydrochlorid abfiltriert. Das Filtrat wird im Vakuum am Rotationsverdampfer eingeengt und derA mixture consisting of 107 g (1.0 mol) of benzylamine, 78 g (0.4 mol) of <x, 3,4-trichlorotoluene and 400 ecm of absolute toluene is refluxed for 15 hours with stirring. After cooling down the precipitated benzylamine hydrochloride is filtered off to room temperature. The filtrate is in Vacuum concentrated on a rotary evaporator and the
Rückstand destilliert. Dabei erhält man das N-Benzyl-N-3,4-dichlorbenzylamin vom Sdp. 177 bis 1797 1,75 mm, n%° = 1,5935.Distilled residue. This gives N-benzyl-N-3,4-dichlorobenzylamine with a bp 177 to 1797 1.75 mm, n% ° = 1.5935.
b) N-Benzyl-N-3,4-dichlorbenzylsulfamidb) N-Benzyl-N-3,4-dichlorobenzylsulfamide
Eine Lösung von 13,2 g (0,05 Mol) N-Benzyl-N-3,4-dichlorbenzylamin und 7,0 g (0,07 Mol) Sulfamid in 100 ecm Pyridin wird unter Rühren so lange am Rückfluß erhitzt, bis keine Gasentwicklung mehr auftritt. Anschließend wird das Lösungsmittel am Rotationsverdampfer im Vakuum entfernt und der viskose Rückstand aus Methanol—Wasser umkristallisiert. Dabei erhält man das N-Benzyl-N-3,4-dichlorbenzylsulfamid vom Schmp. 95 bis 96°.A solution of 13.2 g (0.05 mol) of N-benzyl-N-3,4-dichlorobenzylamine and 7.0 g (0.07 mol) of sulfamide in 100 ecm of pyridine is stirred for so long heated under reflux until no more gas evolution occurs. Then the solvent is on The rotary evaporator was removed in vacuo and the viscous residue was recrystallized from methanol-water. This gives N-benzyl-N-3,4-dichlorobenzylsulfamide from m.p. 95 to 96 °.
Beispiel 3
N-Benzyl-N-2,4-dichlorbenzylsulfamidExample 3
N-Benzyl-N-2,4-dichlorobenzylsulfamide
a) N-Benzyl-N-2,4-dichlorbenzylamina) N-Benzyl-N-2,4-dichlorobenzylamine
Eine Mischung, bestehend aus 53,5 g (0,5 Mol) Benzylamin, 39 g (0,2 Mol) a,2,4-Trichlortoluol und 200 ecm Toluol, wird, wie im Beispiel 2, a) beschrieben, umgesetzt und aufgearbeitet. Das dabei erhaltene N-Benzyl-N-2,4-dichlorbenzylamin hat einen Sdp. von 178 bis 18170,4 mm, nf = 1,5930.A mixture consisting of 53.5 g (0.5 mol) of benzylamine, 39 g (0.2 mol) of a, 2,4-trichlorotoluene and 200 ecm of toluene is, as described in Example 2, a), reacted and worked up. The N-benzyl-N-2,4-dichlorobenzylamine obtained in this way has a boiling point of 178 to 18,170.4 mm, nf = 1.5930.
b) N-Benzyl-N-2,4-dichlorbenzylsuIfamidb) N-Benzyl-N-2,4-dichlorobenzyl sulfamide
Eine Lösung von 13,2 g (0,05 Mol) N-Benzyl-2,4-dichlorbenzylamin und 7,0 g (0,07 Mol) Sulfamid in 40 ecm Pyridin wird unter Rühren am Rückfluß so lange erhitzt, bis keine Gasentwicklung mehr zu beobachten ist. Anschließend wird das Lösungsmittel am Rotationsverdampfer im Vakuum entfernt und der viskose Rückstand aus Methanol—Wasser umkristallisiert. Das dabei erhaltene N-Benzyl-N-2,4-dichlorbenzylsulfamid hat einen Schmp. von 95,5 bis 97°A solution of 13.2 g (0.05 mol) of N-benzyl-2,4-dichlorobenzylamine and 7.0 g (0.07 mol) of sulfamide in 40 ecm of pyridine is refluxed with stirring Heated until no more gas evolution can be observed. Then the solvent removed on a rotary evaporator in vacuo and the viscous residue was recrystallized from methanol-water. The N-benzyl-N-2,4-dichlorobenzylsulfamide obtained has a melting point of 95.5 to 97 °
Beispiel 4
N,N-Bis-(2,4-dichlorbenzyl)-suIfamidExample 4
N, N-bis (2,4-dichlorobenzyl) sulfamide
Eine Lösung von 36,6 g (0,11 Mol) Bis-(2,4-dichlorbenzyl)-amin und 9,6 g (0,10 Mol) Sulfamid in 40 ecm Pyridin wird unter Rühren am Rückfluß so lange erhitzt, bis keine Gasentwicklung mehr zu beobachten ist. Anschließend wird das Lösungsmittel am Rotationsverdampfer im Vakuum entfernt, der viskose Rückstand aus Methanol—Wasser umkristallisiert und dabei das N,N-Bis-(2,4-dichlorbenzyl)-sulfamid erhalten. Schmp. 123 bis 124°.A solution of 36.6 g (0.11 mol) bis (2,4-dichlorobenzyl) amine and 9.6 g (0.10 mol) of sulfamide in 40 ecm of pyridine is refluxed with stirring heated for a long time until no more gas evolution can be observed. Then the solvent removed on a rotary evaporator in vacuo, the viscous residue recrystallized from methanol-water and thereby the N, N-bis (2,4-dichlorobenzyl) sulfamide obtained. 123 to 124 °.
N,N-Bis-(2,4-dichlorbenzyl)-sulfamidN, N-bis (2,4-dichlorobenzyl) sulfamide
Eine Mischung, bestehend aus 21,3 g (0,1 Mol) salzsaurem Salz von 2,4-Dichlorbenzylamin, 11,2 g (0,11 Mol) Triäthylamin, 4,8 g (0,05 Mol) Sulfamid und 150 ecm Pyridin, wird während 8 Stunden unter Rühren am Rückflußkühler erhitzt. Das Lösungsmittel wird anschließend am Rotationsverdampfer entfernt und der Rückstand mit 350 ecm Wasser gewaschen. Das wasserunlösliche Material wird aus Isopropanol umkristallisiert, das dabei erhaltene N,N - Bis - (2,4 - dichlorbenzyl) - sulfamid hat einen Schmp. von 123 bis 124° C.A mixture consisting of 21.3 g (0.1 mol) of the hydrochloric acid salt of 2,4-dichlorobenzylamine, 11.2 g (0.11 mol) of triethylamine, 4.8 g (0.05 mol) of sulfamide and 150 ecm of pyridine is under for 8 hours Stirring heated on the reflux condenser. The solvent is then used on a rotary evaporator removed and the residue washed with 350 ecm of water. The water-insoluble material is made from Isopropanol recrystallized, the N, N - bis (2,4 - dichlorobenzyl) sulfamide obtained has a Mp. From 123 to 124 ° C.
Claims (1)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33935464A | 1964-01-22 | 1964-01-22 | |
US416907A US3318952A (en) | 1964-01-22 | 1964-12-08 | Dibenzylsulfamides |
Publications (1)
Publication Number | Publication Date |
---|---|
DE1231690B true DE1231690B (en) | 1967-01-05 |
Family
ID=26161647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DES95069A Pending DE1231690B (en) | 1964-01-22 | 1965-01-19 | Process for the preparation of N, N-dibenzyl sulfamides |
Country Status (5)
Country | Link |
---|---|
US (1) | US3318952A (en) |
DE (1) | DE1231690B (en) |
ES (1) | ES308359A1 (en) |
FR (2) | FR1451245A (en) |
GB (1) | GB1087601A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996012697A2 (en) * | 1994-10-21 | 1996-05-02 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5981599A (en) * | 1996-05-01 | 1999-11-09 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor active compounds |
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6057346A (en) * | 1994-12-12 | 2000-05-02 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of retroviral LTR promoters by calcium response modifiers |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH618308B (en) * | 1976-06-25 | 1900-01-01 | Ciba Geigy Ag | METHOD FOR FLAME RETAINING TEXTILE MATERIALS MADE OF POLYESTER WITH SUBSTITUTED SULFURYLAMIDES. |
TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
ATE400565T1 (en) * | 2004-08-24 | 2008-07-15 | Janssen Pharmaceutica Nv | NEW BENZOCONDENTED HETEROARYLSULFAMIDE DERIVATIVES SUITABLE AS ANTICONVULSIVE AGENTS |
AU2006249577A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8937096B2 (en) * | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
AR058389A1 (en) * | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | USE OF SULFAMIDE BENZO-FUSED HETEROCICLIC DERIVATIVES FOR THE TREATMENT OF OBESITY |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
TW200812573A (en) * | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
BRPI0915890A2 (en) | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | (2s) - (-) - n- (6-chloro-2,3-dihydro-benzo [1,4] dioxin-2-ylmethyl) sulfamide crystalline form |
US8815939B2 (en) * | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
-
1964
- 1964-12-08 US US416907A patent/US3318952A/en not_active Expired - Lifetime
-
1965
- 1965-01-15 GB GB1962/65A patent/GB1087601A/en not_active Expired
- 1965-01-19 DE DES95069A patent/DE1231690B/en active Pending
- 1965-01-20 ES ES0308359A patent/ES308359A1/en not_active Expired
- 1965-01-21 FR FR2815A patent/FR1451245A/en not_active Expired
- 1965-04-20 FR FR13875A patent/FR4380M/fr not_active Expired
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
WO1996012697A3 (en) * | 1994-10-21 | 1996-06-13 | Nps Pharma Inc | Calcium receptor-active compounds |
WO1996012697A2 (en) * | 1994-10-21 | 1996-05-02 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
EP1553078A1 (en) * | 1994-10-21 | 2005-07-13 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
US6211244B1 (en) | 1994-10-21 | 2001-04-03 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
CN1312116C (en) * | 1994-10-21 | 2007-04-25 | Nps药物有限公司 | Calcium acceptor active compound |
EP1275635A1 (en) * | 1994-10-21 | 2003-01-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
EP1203761A2 (en) * | 1994-10-21 | 2002-05-08 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
EP1203761A3 (en) * | 1994-10-21 | 2002-05-15 | Nps Pharmaceuticals, Inc. | Calcium receptor-active compounds |
RU2195446C2 (en) * | 1994-12-08 | 2002-12-27 | Эн-Пи-Эс Фармасьютикалз, Инк. | Compounds showing activity with respect to calcium receptors (versions), pharmaceutical composition and methods of treatment (versions) |
US6057346A (en) * | 1994-12-12 | 2000-05-02 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of retroviral LTR promoters by calcium response modifiers |
US6342532B1 (en) | 1996-05-01 | 2002-01-29 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor active compounds |
US6710088B2 (en) | 1996-05-01 | 2004-03-23 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor-active compounds |
US5981599A (en) * | 1996-05-01 | 1999-11-09 | Nps Pharmaceuticals, Inc. | Inorganic ion receptor active compounds |
Also Published As
Publication number | Publication date |
---|---|
US3318952A (en) | 1967-05-09 |
FR4380M (en) | 1966-08-29 |
ES308359A1 (en) | 1965-06-01 |
GB1087601A (en) | 1967-10-18 |
FR1451245A (en) | 1966-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE1231690B (en) | Process for the preparation of N, N-dibenzyl sulfamides | |
DE1250450B (en) | Process for the production of amino alcohols and their acid addition salts and quaternary ammonium compounds | |
DE2556110B2 (en) | 2- (3-Alkylamino-2-hydroxypropoxy) -3cyanpyridines, their preparation and pharmaceutical use | |
DE2205815A1 (en) | N-(oxazolin-2-yl)-piperazine - with antitussive activity | |
DE1240846B (en) | Process for the preparation of sulfamides | |
DE2206366B2 (en) | Process for the preparation of substituted diaminocarbonyl derivatives | |
DD151408A5 (en) | METHOD FOR PRODUCING NEW PHARMACEUTICALLY ACTIVE PHENYLPIPERAZINE DERIVATIVES | |
DE1197887B (en) | Process for the preparation of 3-trifluoromethylphenoxazine derivatives | |
AT242150B (en) | Process for the preparation of new, substituted dihydroquinoxalones (2) and their salts and quaternary ammonium compounds | |
DE2162917C3 (en) | ||
DE2809798B2 (en) | Process for the preparation of 5-substituted tetrazoles | |
DE2166270A1 (en) | AMINO ETHANESULFONYL DERIVATIVES | |
DE1543288A1 (en) | Process for the preparation of dibenzocycloheptenylamines | |
DE2402577C3 (en) | Process for the preparation of benzylamines | |
AT256814B (en) | Process for the production of new sulfamides | |
DE2223193C3 (en) | Process for the preparation of 2-amino-benzylamines | |
DE2256740B2 (en) | Process for the preparation of N- (diethylaminoethyl) -2-methoxy-5-methylsulfonyl-benzamide | |
DE2709109B2 (en) | Process for the preparation of 1 -tert-butylamino-3- (2 ^ -dichlorophenoxy) -2-propanol including its enantiomers and its hydrochloride | |
DE1543732C (en) | Process for the preparation of 1,1 diphenyl 1 alkoxy-3 aminopropanes | |
DE1695757C3 (en) | Pyridine methanol carbamates and processes for their preparation | |
DE842345C (en) | Process for the preparation of heterocyclic nitrogen compounds | |
DE838142C (en) | Process for the preparation of 7-chloro-4- [5 '- (N-ethyI-N-2 "- oxäthyl - amino) - pentyl- (2')] - aminochinol'in or its water-soluble salts | |
DE1966104C3 (en) | 2- (N-Acyl) -o-phenylenediamines and process for their preparation | |
AT330190B (en) | PROCESS FOR THE PREPARATION OF NEW 1- (3- (5,6,7,8-TETRAHYDRONAPHTH-1-YL-OXY) -PROPYL) -PIPERAZINE DERIVATIVES AND THEIR SALTS | |
CH549558A (en) | Quaternary immonium salts prodn. |